Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2021

View Archived Issues

Study unveils a mechanistic link between LRRK2, AP2 and endocytosis in the pathogenesis of PD

Inhibition of PIP4K can be used to control regulatory T-cell activity

Novel oxidative-phosphorylation inhibitors with promising antitumor activity in vivo

Discovery of CPL-302415 as promising preclinical candidate for SLE

Loss of fbn2b tied to cardiovascular manifestations overlapping with Marfan syndrome

Eternity Bioscience patents new ADAMTS inhibitors

Fileclo Sp zoo discloses new compounds for cancer

Arbutus Biopharma identifies PD-L1 antagonists

Japanese researchers synthesize new PROTACs for cancer

Rockefeller University presents new LATS1 inhibitors

Biallelic THUMPD1 variants linked to syndromic intellectual developmental disorder

Merck & Co. structure-based design efforts lead to new nucleoside PRMT5 inhibitors

ErSO induces regression of human breast tumors in vivo

Researchers identify genetic associations with behaviors related to self-regulation and addiction

Jacobio invests in Hebecell to advance iPSC-NK cell therapy

AcureX awarded funding to support development of drug candidates for Parkinson's disease

Mindset Pharma reports preclinical data on next-generation novel 5-MeO-DMT psychedelic analogues

COL13A1 and KCNMA1 are downregulated in patients with Pompe disease

Janssen optimizes new series of PDE2A inhibitors

SPOP gene behind prostate cancer risk

All is loss for P53 mutations, study argues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...